September 25th, 2024
Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma
Our product Borofalan (10B) (development code: SPM-011), which we are developin……
Press Release
September 10th, 2024
Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma
Stella Pharma completed the enrollment of patients for the domestic phase II do……
September 6th, 2024
Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT
Stella Pharma announces that it has signed an agreement with the National Cance……
August 30th, 2024
Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma
Stella Pharma announces that it has applied to the Japanese Ministry of Health,……
July 16th, 2024
Specified Clinical Research Contract concluded with Edogawa Hospital
― Providing our drug for Research on FDG-PET-positive shallow tumors ― Stell……
June 24th, 2024
BNCT for Thoracic Malignant Tumor – Submission of Trial Plan Notification for Domestic Clinical Trial Phase I/II
We would like to announce that our company submitted the trial plan notificatio……
May 9th, 2024
BNCT Project in Hong Kong-Shenzhen – Memorandum of Understanding signing ceremony
Together with China Biotech Services Holdings Limited (CBSH), our partner for t……
April 16th, 2024
Paper published: Clinical trial about Boron Neutron Capture Therapy for recurrent breast cancer
Our company provides Steboronine® for the investigator-initiated specified clin……
The international science journal “Nature” published in its special edition “Ra……
March 14th, 2024
Observation period completed for primary endpoint – Phase II study in patients with recurrent high-grade meningioma
Our company provides the boron drug for BNCT (Boron Neutron Capture Therapy), w……
March 4th, 2024
Interim Analysis Results of Post-Marketing Surveillance of Our Drug Product published ― Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer
The results regarding safety and effectiveness of our product Borofalan(10B), u……
January 11th, 2024
Investigator-initiated Phase I BNCT clinical trial for newly diagnosed glioblastoma
We would like to announce that Phase I clinical trial for newly diagnosed gliob……
